GSK acquires Nuvalent for $10.6 billion, bolstering cancer drug pipeline

By EC Assets · Published 9 June 2026

British pharmaceutical company GSK agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion. The deal represents GSK's largest acquisition in years and the biggest in over a decade. This move aims to strengthen GSK's cancer portfolio. GSK will acquire Nuvalent for $10.6 billion, offering $124 per share in cash. This price represents a 40% premium to Nuvalent's last closing price. The acquisition is intended to boost GSK’s lung cancer portfolio. The deal includes late-stage NSCLC inhibitors. The acquisition reinforces GSK's drug lineup for treating lung cancer. This acquisition marks a strategic shift for GSK under its new CEO, as the company seeks to bolster its cancer portfolio, which it had previously trimmed. GSK had been in talks to acquire Nuvalent for more than $9 billion. Reports prior to the agreement indicated a potential deal valued between $9 billion and $10 billion. This article is intended for informational purposes only. It does not constitute investment advice.